Ketorolac in Upper Extremity Tendinopathy and Arthropathy

Launched by EMORY UNIVERSITY · Mar 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of two types of injections—ketorolac and triamcinolone—for treating pain and inflammation in the shoulder, elbow, wrist, and hand due to conditions like osteoarthritis and tendon injuries. The goal is to see which injection helps patients feel better and improve their ability to move. The trial is taking place at the Emory Sports Medicine Complex and other Emory locations, and it is currently recruiting participants.

To be eligible for the study, you need to be at least 18 years old and have painful tendon or joint issues in your upper extremities that haven't been treated with surgery. Conditions that qualify include things like trigger finger and different types of arthritis in the hand and wrist. If you join the study, you won’t know which injection you receive, and you'll have a follow-up visit six weeks after the injection to see how you’re doing. The entire study lasts about 24 weeks, and the results will help doctors understand the best ways to manage these common and often disabling conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 or older,
• • symptomatic tendinopathy or arthropathy of the shoulder, elbow, hand, or wrist who have not undergone prior surgical treatment for their condition.
• • Diagnoses may include trigger finger, De Quervain's tenosynovitis, radiocarpal osteoarthritis, first carpometacarpal (CMC) joint osteoarthritis, metacarpophalangeal joint osteoarthritis, or proximal interphalangeal joint osteoarthritis.
• Exclusion Criteria:
• • Patients under the age of 18,
• • Patients who have undergone prior triamcinolone or ketorolac injections within the past 6 months,
• • Patients who have undergone prior surgical treatment for their hand condition,
• • Patients with allergy or contraindication to triamcinolone or ketorolac injection,
• • Patients with an active infection at the treatment site \[active infection defined as cellulitis, purulence, fever, chills, or presence of elevated inflammatory markers, ie. white blood cells (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)\].